Core Viewpoint - Organon & Co. is facing a class action lawsuit due to significant changes in its dividend policy and alleged misleading statements regarding its financial health and business strategy [1][3]. Financial Performance - On May 1, 2025, Organon reported its Q1 2025 financial results, announcing a drastic reduction in its dividend payout from $0.28 to $0.02, reallocating funds towards debt reduction [2]. - Following this announcement, Organon's stock price dropped by $3.48, or 26.9%, closing at $9.45 per share on the same day [2]. Lawsuit Details - The class action complaint alleges that during the Class Period, Organon made materially false and misleading statements and failed to disclose adverse facts about its business and operations [3]. - Specific allegations include the misleading portrayal of the dividend payout as a priority while simultaneously implementing a debt reduction strategy that led to a more than 70% decrease in the quarterly dividend [3]. - The lawsuit claims that the positive statements made by the company regarding its business prospects lacked a reasonable basis and were materially misleading [3]. Legal Action - Investors who purchased Organon securities during the Class Period have until July 22, 2025, to file a lead plaintiff motion in the class action lawsuit [1][4].

Key Takeaways PATH trades at a 4.37x forward P/S, below 5.68x of the industry average, suggesting relative undervaluation. Strong recurring revenues, global expansion and AI integrations support PATH's enterprise momentum. PATH's valuation trails peers like NOW and PEGA, despite faster growth and a focused automation strategy.UiPath Inc. (PATH) appears attractively valued compared with its industry peers based on the forward 12-month price-to-sales (P/S) ratio. Currently trading at 4.37x, PATH’s valuation ...

CHICAGO, June 13, 2025 /PRNewswire/ -- McDonald's USA, LLC and Entertainment Studios Network/The Weather Group today announced an agreement to settle pending litigation between them. The parties reached a confidential commercial agreement whereby McDonald's will continue to purchase advertising from ESN in a manner that aligns with its advertising strategy and commercial objectives and ESN will dismiss its lawsuit against McDonald's in the United States District Court for the Central District of California. ...

Biotechnology research firm Thermo Fisher Scientific is reportedly looking to sell part of its diagnostics business amid industrywide concerns about federal cutbacks in spending on research.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no add ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

My recent coverage of UroGen Pharma (NASDAQ: URGN ) was the prospective risk-taker's manifesto on a very shaky FDA decision. Now that this thesis has worked out, the "predictions" laid out in that article appear to be nearlyI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the p ...

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Compass Diversified Holdings (NYSE: CODI) between May 1, 2024, and May 7, 2025, both dates inclusive (the “Class Period”), of the important July 8, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Compass securities you may be entitled to compensation without payment of any out of pocket fees or costs through a ...

Core Insights - Adobe Inc. reported second-quarter revenue of $5.87 billion, exceeding analyst estimates of $5.79 billion, and adjusted earnings of $5.06 per share, surpassing the expected $4.96 per share [1][2] - The company raised its full-year 2025 revenue guidance to a range of $23.5 to $23.6 billion, up from the previous guidance of $23.3 billion to $23.55 billion, and adjusted earnings guidance to $20.50 to $20.70 per share, increased from $20.20 to $20.50 per share [3] Financial Performance - For the third quarter, Adobe expects revenue between $5.88 billion and $5.93 billion, compared to estimates of $5.87 billion, and anticipates adjusted earnings of $5.15 to $5.20 per share, against estimates of $5.10 per share [2] - Following the earnings announcement, Adobe shares fell by 5.8% to $389.64 [3] Analyst Ratings and Price Targets - Wells Fargo analyst Michael Turrin maintained an Overweight rating and raised the price target from $430 to $470 [6] - Oppenheimer analyst Brian Schwartz maintained an Outperform rating but lowered the price target from $530 to $500 [6] - Evercore ISI Group analyst Kirk Materne reiterated an Outperform rating with a maintained price target of $475, while BMO Capital analyst Keith Bachman also reiterated an Outperform rating with a price target of $450 [6]

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive an ...

Key Takeaways Block is expanding Square and Cash App, but faces macro pressures and slowing discretionary spending. Upstart's AI-driven lending saw 67% revenue growth and a shift to profitability in Q1 2025. While XYZ trades cheaper, UPST's expanding credit portfolio and AI upgrades drive upside potential.The fintech sector is evolving fast, driven by innovation in digital payments, credit underwriting, and user experience. Two major players — Block, Inc. (XYZ) and Upstart Holdings (UPST) — stand out for ...